• February 10, 2015
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that it has completed the purchase of the animal health assets of Abbott for a purchase price of $255 million, having fulfilled all closing requirements. The purchase expands Zoetis’ companion animal product portfolio to bring veterinarians solutions for anesthesia and treating pain and serious illnesses such as diabetes. It also brings novel cancer and pain compounds to the Zoetis pipelinemore...
  • January 7, 2015
    FLORHAM PARK, N.J., Jan. 7, 2015 — Fostera® PRRS, from Zoetis, is now licensed for whole herd protection against both the respiratory and reproductive forms of disease caused by porcine reproductive and respiratory syndrome (PRRS) virus.The new reproductive claim, recently granted by the U.S. Department of Agriculture (USDA), allows for vaccination of sows and gilts prebreeding to help provide protection against the reproductive form of the disease. The new respiratory claim allows formore...
  • November 24, 2014
    DURHAM, N.C. - November 24, 2014 – Zoetis Inc. today announced the reintroduction of Zoamix® (zoalene), a versatile synthetic anticoccidial for the prevention and control of coccidiosis in broilers and turkeys.“The U.S. poultry industry loses an estimated $600 million a year to coccidiosis[i], so the return of Zoamix could not be coming at a better time,” said Don Waldrip, DVM, DACPV, a senior technical services veterinarian with Zoetis.He noted that U.S. poultry producers have not seen a newmore...
  • September 25, 2014
    FLORHAM PARK, NJ, Sept. 25, 2014 — Zoetis now offers a test to quickly and accurately screen for the detection of antibodies to Johne’s Disease in cattle, the company announced today.Matthew Krecic, DVM, MS, MBA, DACVIM, Senior Technical Services Manager of U.S. Diagnostics, Zoetis, said the test uses an indirect immunoenzymatic technique to detect Mycobacterium avium, subspecies paratuberculosis (M. ParaTB) antibodies in samples of cattle serum and plasma. Results are available in less thanmore...
  • September 3, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Department of Agriculture (USDA) has granted a conditional license for a vaccine to help fight porcine epidemic diarrhea virus (PEDv) in pigs. The two-dose inactivated vaccine, licensed for use in healthy pregnant female pigs (sows and gilts), is designed to help them develop antibodies which can be transmitted to their newborn piglets. Zoetis anticipates the vaccine will be available tomore...
  • August 20, 2014
    FLORHAM PARK, N.J., Aug. 20, 2014 — Fostera™ PCV MH — the porcine circovirus (PCV) and Mycoplasma hyopneumoniae (M. hyo) combination vaccine that was built from the ground up by Zoetis — now has the longest demonstrated duration of immunity (DOI) to help protect pigs from porcine circovirus-associated disease (PCVAD) caused by PCV Type 2 (PCV2). The U.S. Department of Agriculture has granted the combination vaccine the extended label claim of at least 23 weeks of protection against PCV2, whichmore...
  • February 7, 2014
    DURHAM, N.C. - February 7, 2014 – Zoetis Inc. has obtained a conditional license from the U.S. Department of Agriculture (USDA) to market  the first commercially available vaccine for helping reduce disease caused by the Georgia 08 variant of infectious bronchitis virus (IBV) in poultry*. The vaccine is now available in Alabama, Florida, Georgia, Kentucky and Tennessee. The USDA agreed to issue a conditional license because the modified-live vaccine fills a special need, has beenmore...
  • January 29, 2014
    PARIS, FRANCE, January 29, 2014 – Zoetis Inc. announced today the launch of Apoquel® (oclacitinib maleate), a novel therapy indicated for the treatment of pruritus (itching) associated with canine allergic dermatitis and the clinical manifestations of atopic dermatitis. Veterinarians across Europe now have a first-in-class treatment choice that targets the itch of allergic skin conditions in dogs.Apoquel is the first Janus Kinase (JAK) inhibitor approved for veterinary use. It provides rapidmore...
  • October 1, 2013
    FLORHAM PARK, N.J., October 1, 2013 – Zoetis Inc., (NYSE: ZTS) formerly the animal health business unit of Pfizer Inc., has notified the U.S. Food and Drug Administration (FDA) that the company will voluntarily withdraw the marketing authorizations (New Animal Drug Applications) for 3-Nitro (roxarsone)  and Carb-O-Sep ® (carbarsone). The decision to withdraw the marketing authorization for 3-Nitro, a feed medicine containing the organic arsenical roxarsone, follows the suspension ofmore...
  • August 4, 2013
    HUINAN, JILIN, China--(BUSINESS WIRE)--Zoetis today announced that its joint venture in China received the approval by the Ministry of Agriculture of the People’s Republic of China for Rui Lan An™, a specialized vaccine to help control the highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS). Rui Lan An, which will be launched later this month, is the first vaccine to emerge from the joint venture that was established to develop and manufacture animal vaccinesmore...